公开(公告)号：US20200063214A1

公开(公告)日：2020-02-27

申请号：US16525026

申请日：2019-07-29

申请人： Geron Corporation

发明人： Jacqueline Cirillo BUSSOLARI ,  Fei HUANG

IPC分类号： C12Q1/6886 ,  G16H50/30 ,  G16B40/10 ,  C12Q1/6827 ,  A61K9/00 ,  G16H20/10 ,  A61K31/7105 ,  A61K47/54

摘要： This disclosure provides methods of identifying or selecting a patient most likely to benefit from treatment with a telomerase inhibitor, such as e.g. imetelstat, by testing a patient for: a lack of a mutation in each of JAK2, CALR, and MPL; and/or a high-molecular risk (HMR), based on the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2, and IDH1/2. The patient may be suffering from myelofibrosis. The disclosure also provides methods of treating myelofibrosis, which include identifying such patients.

公开(公告)号：US20200171072A1

公开(公告)日：2020-06-04

申请号：US16696103

申请日：2019-11-26

申请人： Geron Corporation

发明人： Jacqueline Cirillo BUSSOLARI ,  Fei HUANG ,  Aleksandra RIZO

IPC分类号： A61K31/7125 ,  A61K31/4439 ,  A61K31/706 ,  A61P35/00

摘要： Methods of monitoring therapeutic efficacy in a subject with MDS are provided. Also provided is a method of identifying a subject with myelodysplastic syndrome (MDS) for treatment with a telomerase inhibitor, and methods of treating MDS. The subject methods can include administering to the subject an effective amount of a telomerase inhibitor and assessing the hTERT expression levels in a biological sample obtained from the subject. In some cases, a 50% or greater reduction in hTERT expression level identifies a subject who has an increased likelihood of benefiting from treatment with the telomerase inhibitor. The subject can be naive to treatment with a HMA, lenalidomide, or both. In some cases, the subject is classified as having low or intermediate-1 IPSS risk MDS and/or MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA). In some instances, the telomerase inhibitor is imetelstat sodium.